Issue highlights
New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives
Rituximab in the treatment of autoimmune haemolytic anaemia
Lessons learned from the clinical development of oral peptides
Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus – a systematic review and meta-analysis
Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects
Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor
Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease
A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis
Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi
Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662
Pharmacokinetic–pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers
Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy
Doctors' perspectives on the barriers to appropriate prescribing in older hospitalized patients: a qualitative study
Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and non-diabetic patients
Confounding by alcohol use: benzodiazepines and risk of liver cancer